» Articles » PMID: 32257540

Disease Progression-Dependent Expression of CD200R1 and CX3CR1 in Mouse Models of Parkinson's Disease

Overview
Journal Aging Dis
Specialty Geriatrics
Date 2020 Apr 8
PMID 32257540
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Microglial activation is an important contributor to the pathogenesis of Parkinson's disease (PD). Microglia are tightly and efficiently regulated by immune checkpoints, including CD200-CD200R1 and CX3CL1-CX3CR1. Understanding the involvement of these checkpoints in disease progression provides important insights into how microglial activation contributes to PD pathology. However, so far, studies have produced seemingly conflicting results. In this study, we demonstrate that CD200R1 expression is down-regulated at both early and late stage of PD model, and CX3CR1 expression is down-regulated in early stage and recovered in late stage. In primary cultured microglia, CD200R1 and CX3CR1 expressions are both directly regulated by LPS or α-synuclein, and CD200R1 expression is more sensitively regulated than CX3CR1. In addition, CD200 knockout causes an increase in proinflammatory cytokine production and microglial activation in the midbrain. Remarkably, DA neurons in the substantial nigra are degenerated in CD200 mice. Finally, activation of the CD200R with CD200Fc alleviates the neuroinflammation in microglia. Together, these results suggest that immune checkpoints play distinct functional roles in different stage of PD pathology, and the CD200-CD200R1 axis plays a significant role in nigrostriatal neuron viability and function.

Citing Articles

CX3CL1 Regulation of Gliosis in Neuroinflammatory and Neuroprotective Processes.

Gutierrez I, Martin-Hernandez D, MacDowell K, Garcia-Bueno B, Caso J, Leza J Int J Mol Sci. 2025; 26(3).

PMID: 39940727 PMC: 11817243. DOI: 10.3390/ijms26030959.


Glial cells improve Parkinson's disease by modulating neuronal function and regulating neuronal ferroptosis.

Li M, Chen M, Li H, Gao D, Zhao L, Zhu M Front Cell Dev Biol. 2025; 12():1510897.

PMID: 39830208 PMC: 11739109. DOI: 10.3389/fcell.2024.1510897.


Microglia depletion reduces neurodegeneration and remodels extracellular matrix in a mouse Parkinson's disease model triggered by α-synuclein overexpression.

Zhang Z, Niu K, Huang T, Guo J, Xarbat G, Gong X NPJ Parkinsons Dis. 2025; 11(1):15.

PMID: 39779738 PMC: 11711755. DOI: 10.1038/s41531-024-00846-4.


Evaluation of a Synthetic Retinoid, Ellorarxine, in the NSC-34 Cell Model of Motor Neuron Disease.

Escudier O, Zhang Y, Whiting A, Chazot P Int J Mol Sci. 2024; 25(18).

PMID: 39337251 PMC: 11431449. DOI: 10.3390/ijms25189764.


The regulation of NFKB1 on CD200R1 expression and their potential roles in Parkinson's disease.

Lin S, Shu Y, Shen R, Zhou Y, Pan H, He L J Neuroinflammation. 2024; 21(1):229.

PMID: 39294682 PMC: 11409543. DOI: 10.1186/s12974-024-03231-3.


References
1.
Kierdorf K, Prinz M . Factors regulating microglia activation. Front Cell Neurosci. 2013; 7:44. PMC: 3632747. DOI: 10.3389/fncel.2013.00044. View

2.
Santoni G, Cardinali C, Morelli M, Santoni M, Nabissi M, Amantini C . Danger- and pathogen-associated molecular patterns recognition by pattern-recognition receptors and ion channels of the transient receptor potential family triggers the inflammasome activation in immune cells and sensory neurons. J Neuroinflammation. 2015; 12:21. PMC: 4322456. DOI: 10.1186/s12974-015-0239-2. View

3.
Brown G, Neher J . Microglial phagocytosis of live neurons. Nat Rev Neurosci. 2014; 15(4):209-16. DOI: 10.1038/nrn3710. View

4.
Masocha W . Systemic lipopolysaccharide (LPS)-induced microglial activation results in different temporal reduction of CD200 and CD200 receptor gene expression in the brain. J Neuroimmunol. 2009; 214(1-2):78-82. DOI: 10.1016/j.jneuroim.2009.06.022. View

5.
Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M . Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One. 2010; 5(1):e8784. PMC: 2808388. DOI: 10.1371/journal.pone.0008784. View